 |
 |
|
 |
|
|
PUBLICATIONS
The inventors and investigators of Bradmer Pharmaceuticals' first product candidate, Neuradiab, have extensively published their findings in peer-reviewed journals. Such findings describe the molecular target (tenascin), the drug itself, the dosimetry and delivery methods employed, and the clinical trials that have been previously conducted. Below, a sampling of these publications is provided:
"A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost." Reardon et al. Neuro Oncol.2008; 0: 15228517-2007-053v1 Read More
“Salvage Radioimmunotherapy with Murine Iodine-131-Labeled Antitenascin Monoclonal Antibody 81C6 for Patients with Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results." Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Guruangan S, Badruddoja M, Dowell JM, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD, J Clin Oncol. 2006 Jan; 24:115-122 Read More
"Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.” Akabani G, Reardon DA, Coleman RE, Wong TZ, Metzler SD, Bowsher JE, Barboriak DP, Provenzale JM, Greer KL, DeLong D, Friedman HS, Friedman AH, Zhao XG, Pegram CN, McLendon RE, Bigner DD, Zalutsky MR., J Nucl Med. 2005 Jun;46 (6):1042-51Read More
“Monoclonal antibodies for brain tumour treatment.” Boskovitz A, Wikstrand CJ, Kuan CT, Zalutsky MR, Reardon DA, Bigner DD. Expert Opin Biol Ther. 2004 Sep;4 (9):1453-71Read More
“Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.” Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, Wikstrand CJ, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD. J Clin Oncol. 2002 Mar 1;20(5):1389-97. Read More
“Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.” Cokgor I, Akabani G, Kuan CT, Friedman HS, Friedman AH, Coleman RE, McLendon RE, Bigner SH, Zhao XG, Garcia-Turner AM, Pegram CN, Wikstrand CJ, Shafman TD, Herndon JE 2nd, Provenzale JM, Zalutsky MR, Bigner DD. J Clin Oncol. 2000 Nov 15;18(22):3862-72Read More
“Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy.” Akabani G, Cokgor I, Coleman RE, Gonzalez Trotter D, Wong TZ, Friedman HS, Friedman AH, Garcia-Turner A, Herndon JE, DeLong D, McLendon RE, Zhao XG, Pegram CN, Provenzale JM, Bigner DD, Zalutsky MR. Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):947-58Read More
 * Note: Links will open in PDF format |
|
|
|
|
|
